Long-term AREDS2 follow-up supported replacing beta carotene with lutein and zeaxanthin. The revised formula retained benefit for people at risk of late AMD without increasing lung-cancer risk.
doi: 10.1001/jamaophthalmol.2022.1640Two phase 3 trials compared faricimab with aflibercept in neovascular AMD. Faricimab produced comparable visual-acuity outcomes and allowed longer injection intervals for some patients.
doi: 10.1016/S0140-6736(22)00010-1A meta-analysis estimated depression and anxiety across AMD, diabetic retinopathy, glaucoma and other causes of vision loss.
doi: 10.1177/00912174251382653The review organised multimodal-imaging features of age-related choroidal atrophy.
doi: 10.1016/j.survophthal.2025.12.005A systematic review compared economic models for drugs used in neovascular AMD.
doi: 10.1016/j.vhri.2025.101542A systematic review included 42 machine-learning studies of AMD detection on colour fundus images.
doi: 10.1016/j.survophthal.2025.10.004The study compared volumetric intraretinal and subretinal fluid measures with conventional central retinal thickness.
doi: 10.1111/aos.70000